{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:32:35Z","timestamp":1780410755300,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Focal adhesion kinase 1 (FAK1) is a non-receptor tyrosine kinase involved in cancer metastasis and tumor progression. Due to its role in regulating cell migration and survival, FAK1 is considered a promising target for cancer therapy. While large chemical databases such as ZINC offer a wide variety of molecules, many of them have not yet been explored as potential FAK1 inhibitors.In this study, we applied several computational methods to identify new inhibitors of the FAK1 kinase domain. Pharmacophore models were built based on the FAK1\u2013P4N complex (PDB ID: 6YOJ), and the most statistically reliable model was used to screen compounds from the ZINC database. Hits were first docked using AutoDock Vina in PyRx, and seventeen compounds with acceptable pharmacokinetic properties and low predicted toxicity were selected for more precise docking via SwissDock. Four promising candidates\u2014ZINC23845603, ZINC44851809, ZINC266691666, and ZINC20267780\u2014were chosen for molecular dynamics (MD) simulations using GROMACS. The stability and behavior of each protein\u2013ligand complex were examined, and binding free energies were calculated using the MM\/PBSA method. Among them, ZINC23845603 showed strong binding and interaction features similar to the known ligand P4N. Given its favorable binding energy and pharmacokinetic profile, ZINC23845603 may be a good candidate for further experimental studies targeting FAK1.<\/jats:p>","DOI":"10.1038\/s41598-025-23203-8","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:17:45Z","timestamp":1762885065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structure-based identification of novel FAK1 inhibitors using pharmacophore modeling, molecular dynamics, and MM\/PBSA calculations"],"prefix":"10.1038","volume":"15","author":[{"given":"Amirhossein","family":"Hajipasha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofar Ghaffari","family":"Cherati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Darzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Sana","family":"Nateghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Arshia Sadat","family":"Mohsenian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"Noorzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh Kashiri","family":"Dinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"23203_CR1","doi-asserted-by":"crossref","unstructured":"Le Coq, J. et al. New insights into FAK structure and function in focal adhesions. J. Cell. Sci., 135(20), jcs259089 (2022).","DOI":"10.1242\/jcs.259089"},{"issue":"3","key":"23203_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/1568009618666180706165222","volume":"19","author":"A Levy","year":"2019","unstructured":"Levy, A. et al. Focal adhesion kinase in ovarian cancer: A potential therapeutic target for platinum and Taxane-Resistant tumors. Curr. Cancer Drug Targets. 19 (3), 179\u2013188 (2019).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"9","key":"23203_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer. 14 (9), 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"23203_CR4","doi-asserted-by":"crossref","unstructured":"Aboubakar Nana, F., Vanderputten, M. & Ocak, S. Role of focal adhesion kinase in Small-Cell lung cancer and its potential as a therapeutic target. Cancers (Basel), 11(11), 1683 (2019).","DOI":"10.3390\/cancers11111683"},{"issue":"6","key":"23203_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2007.05.041","volume":"129","author":"D Lietha","year":"2007","unstructured":"Lietha, D. et al. Structural basis for the autoinhibition of focal adhesion kinase. Cell 129 (6), 1177\u20131187 (2007).","journal-title":"Cell"},{"issue":"5","key":"23203_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones, S. F. et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest. New. Drugs. 33 (5), 1100\u20131107 (2015).","journal-title":"Invest. New. Drugs"},{"issue":"5","key":"23203_CR7","doi-asserted-by":"publisher","first-page":"p1004","DOI":"10.1093\/carcin\/bgs120","volume":"33","author":"VM Golubovskaya","year":"2012","unstructured":"Golubovskaya, V. M. et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 33 (5), p1004\u2013p1013 (2012).","journal-title":"Carcinogenesis"},{"issue":"34","key":"23203_CR8","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.2174\/0929867328666210331143827","volume":"28","author":"P Lv","year":"2021","unstructured":"Lv, P., Chen, K. & Zhu, H. L. Recent advances of small molecule focal adhesion kinase (FAK) inhibitors as promising anticancer therapeutics. Curr. Med. Chem. 28 (34), 6977\u20136989 (2021).","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"23203_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12672-021-00449-y","volume":"12","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Focal adhesion kinase inhibitors, a heavy punch to cancer. Discov Oncol. 12 (1), 52 (2021).","journal-title":"Discov Oncol."},{"issue":"17","key":"23203_CR10","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.2174\/0929867327666201103162239","volume":"28","author":"C Brullo","year":"2021","unstructured":"Brullo, C. & Tasso, B. New insights on Fak and Fak inhibitors. Curr. Med. Chem. 28 (17), 3318\u20133338 (2021).","journal-title":"Curr. Med. Chem."},{"issue":"19","key":"23203_CR11","doi-asserted-by":"publisher","first-page":"e202300141","DOI":"10.1002\/cbic.202300141","volume":"24","author":"E Koide","year":"2023","unstructured":"Koide, E. et al. Development and characterization of selective FAK inhibitors and protacs with in vivo activity. Chembiochem 24 (19), e202300141 (2023).","journal-title":"Chembiochem"},{"issue":"2","key":"23203_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11030-022-10438-0","volume":"27","author":"A Khan","year":"2023","unstructured":"Khan, A. et al. Repositioning of experimentally validated anti-breast cancer peptides to target FAK-PAX complex to halt the breast cancer progression: a biomolecular simulation approach. Mol. Divers. 27 (2), 603\u2013618 (2023).","journal-title":"Mol. Divers."},{"key":"23203_CR13","unstructured":"Furqan, M. et al. Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma."},{"issue":"16_suppl","key":"23203_CR14","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","volume":"41","author":"SN Banerjee","year":"2023","unstructured":"Banerjee, S. N. et al. Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: A phase 2 study of Avutometinib (VS-6766)\u2009\u00b1\u2009defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J. Clin. Oncol. 41 (16_suppl), 5515\u20135515 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"23203_CR15","doi-asserted-by":"publisher","first-page":"31371","DOI":"10.1021\/acsami.1c00388","volume":"13","author":"J Cha","year":"2021","unstructured":"Cha, J. & Kim, P. Cancer cell-Sticky hydrogels to target the cell membrane of invading glioblastomas. ACS Appl. Mater. Interfaces. 13 (27), 31371\u201331378 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"23203_CR16","doi-asserted-by":"publisher","first-page":"108789","DOI":"10.1016\/j.jmgm.2024.108789","volume":"130","author":"V Kumar","year":"2024","unstructured":"Kumar, V. et al. Computational insights into allosteric Inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach. J. Mol. Graph Model. 130, 108789 (2024).","journal-title":"J. Mol. Graph Model."},{"issue":"36","key":"23203_CR17","doi-asserted-by":"publisher","first-page":"32442","DOI":"10.1021\/acsomega.2c03951","volume":"7","author":"M Shi","year":"2022","unstructured":"Shi, M. et al. Molecular Docking, molecular dynamics Simulations, and free energy calculation insights into the binding mechanism between VS-4718 and focal adhesion kinase. ACS Omega. 7 (36), 32442\u201332456 (2022).","journal-title":"ACS Omega"},{"issue":"23","key":"23203_CR18","doi-asserted-by":"publisher","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","volume":"63","author":"Y Lu","year":"2020","unstructured":"Lu, Y. & Sun, H. Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK). J. Med. Chem. 63 (23), 14382\u201314403 (2020).","journal-title":"J. Med. Chem."},{"issue":"11","key":"23203_CR19","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","volume":"27","author":"JS Paradis","year":"2021","unstructured":"Paradis, J. S. et al. Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-Driven uveal melanoma. Clin. Cancer Res. 27 (11), 3190\u20133200 (2021).","journal-title":"Clin. Cancer Res."},{"key":"23203_CR20","doi-asserted-by":"publisher","first-page":"619317","DOI":"10.3389\/fonc.2020.619317","volume":"10","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Doxycycline inhibits cancer stem Cell-Like properties via PAR1\/FAK\/PI3K\/AKT pathway in pancreatic cancer. Front. Oncol. 10, 619317 (2020).","journal-title":"Front. Oncol."},{"issue":"1","key":"23203_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11033-025-10296-7","volume":"52","author":"J Aakriti","year":"2025","unstructured":"Aakriti, J. et al. Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors. Mol. Biol. Rep. 52 (1), 248 (2025).","journal-title":"Mol. Biol. Rep."},{"key":"23203_CR22","doi-asserted-by":"crossref","unstructured":"Gimeno, A. et al. The light and dark sides of virtual screening: what is there to know?. Int. J. Mol. Sci., 20(6), 1375 (2019).","DOI":"10.3390\/ijms20061375"},{"issue":"3","key":"23203_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/17460441.2013.761204","volume":"8","author":"S Kar","year":"2013","unstructured":"Kar, S. & Roy, K. How Far can virtual screening take Us in drug discovery? Expert Opin. Drug Discov. 8 (3), 245\u2013261 (2013).","journal-title":"Expert Opin. Drug Discov"},{"key":"23203_CR24","doi-asserted-by":"crossref","unstructured":"Lin, X., Li, X. & Lin, X. A Rev. Appl. Comput. Methods Drug Screen. Des. Molecules, 25(6), 1375 (2020).","DOI":"10.3390\/molecules25061375"},{"key":"23203_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pbiomolbio.2021.05.004","volume":"164","author":"H Singh","year":"2021","unstructured":"Singh, H. & Bharadvaja, N. Treasuring the computational approach in medicinal plant research. Prog Biophys. Mol. Biol. 164, 19\u201332 (2021).","journal-title":"Prog Biophys. Mol. Biol."},{"issue":"20","key":"23203_CR26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2174\/1568026618666181025114157","volume":"18","author":"AAT Naqvi","year":"2018","unstructured":"Naqvi, A. A. T. et al. Advancements in Docking and molecular dynamics simulations towards Ligand-receptor interactions and Structure-function relationships. Curr. Top. Med. Chem. 18 (20), 1755\u20131768 (2018).","journal-title":"Curr. Top. Med. Chem."},{"key":"23203_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"P Sledz","year":"2018","unstructured":"Sledz, P. & Caflisch, A. Protein structure-based drug design: from Docking to molecular dynamics. Curr. Opin. Struct. Biol. 48, 93\u2013102 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"5","key":"23203_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.chembiol.2021.01.003","volume":"28","author":"BT Berger","year":"2021","unstructured":"Berger, B. T. et al. Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. Cell. Chem. Biol. 28 (5), 686\u2013698e7 (2021).","journal-title":"Cell. Chem. Biol."},{"issue":"p. 5 6 1\u20135","key":"23203_CR29","first-page":"637","volume":"54","author":"B Webb","year":"2016","unstructured":"Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinf. 54 (p. 5 6 1\u20135), 637 (2016).","journal-title":"Curr. Protoc. Bioinf."},{"key":"23203_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471250953.bi0506s47","volume":"47","author":"B Webb","year":"2014","unstructured":"Webb, B. & Sali, A. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinf. 47, 1\u201332 (2014).","journal-title":"Curr. Protoc. Bioinf."},{"issue":"9","key":"23203_CR31","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1110\/ps.9.9.1753","volume":"9","author":"A Fiser","year":"2000","unstructured":"Fiser, A., Do, R. K. & Sali, A. Modeling of loops in protein structures. Protein Sci. 9 (9), 1753\u20131773 (2000).","journal-title":"Protein Sci."},{"key":"23203_CR32","doi-asserted-by":"crossref","unstructured":"Giordano, D. et al. Drug design by pharmacophore and virtual screening approach. Pharmaceuticals (Basel), 15(5), 646 (2022).","DOI":"10.3390\/ph15050646"},{"key":"23203_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymeth.2014.10.013","volume":"71","author":"A Vuorinen","year":"2015","unstructured":"Vuorinen, A. & Schuster, D. Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods 71, 113\u2013134 (2015).","journal-title":"Methods"},{"issue":"14","key":"23203_CR34","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger, M. M. et al. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55 (14), 6582\u20136594 (2012).","journal-title":"J. Med. Chem."},{"issue":"9","key":"23203_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1568026611313090010","volume":"13","author":"RC Braga","year":"2013","unstructured":"Braga, R. C. & Andrade, C. H. Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? Curr. Top. Med. Chem. 13 (9), 1127\u20131138 (2013).","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"23203_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1021\/ci050034w","volume":"45","author":"JM Yang","year":"2005","unstructured":"Yang, J. M. et al. Consensus scoring criteria for improving enrichment in virtual screening. J. Chem. Inf. Model. 45 (4), 1134\u20131146 (2005).","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"23203_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","volume":"24","author":"LLG Ferreira","year":"2019","unstructured":"Ferreira, L. L. G. & Andricopulo, A. D. ADMET modeling approaches in drug discovery. Drug Discov Today. 24 (5), 1157\u20131165 (2019).","journal-title":"Drug Discov Today"},{"key":"23203_CR38","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"issue":"W1","key":"23203_CR39","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee, P. et al. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46 (W1), W257\u2013W263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"23203_CR40","doi-asserted-by":"crossref","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule Docking web service based on EADock DSS. Nucleic Acids Res. 39, W270\u2013W277 (2011).","DOI":"10.1093\/nar\/gkr366"},{"issue":"10","key":"23203_CR41","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/jcc.21797","volume":"32","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. Fast Docking using the CHARMM force field with EADock DSS. J. Comput. Chem. 32 (10), 2149\u20132159 (2011).","journal-title":"J. Comput. Chem."},{"issue":"1","key":"23203_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell, M. D. et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4 (1), 17 (2012).","journal-title":"J. Cheminform"},{"issue":"13","key":"23203_CR43","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (13), 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"23203_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19\u201325 (2015).","journal-title":"SoftwareX"},{"issue":"11","key":"23203_CR45","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.21816","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete, V. et al. SwissParam: a fast force field generation tool for small organic molecules. J. Comput. Chem. 32 (11), 2359\u20132368 (2011).","journal-title":"J. Comput. Chem."},{"issue":"9","key":"23203_CR46","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus, M. & McCammon, J. A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9 (9), 646\u2013652 (2002).","journal-title":"Nat. Struct. Biol."},{"issue":"49","key":"23203_CR47","doi-asserted-by":"publisher","first-page":"12027","DOI":"10.1021\/acs.jpcb.4c06614","volume":"128","author":"B Roux","year":"2024","unstructured":"Roux, B. & Chipot, C. Editorial guidelines for computational studies of ligand binding using MM\/PBSA and MM\/GBSA approximations wisely. J. Phys. Chem. B. 128 (49), 12027\u201312029 (2024).","journal-title":"J. Phys. Chem. B"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23203-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:17:46Z","timestamp":1762885066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23203-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23203"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23203-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39506"}}